



David Eidelberg, MD
Head, Center for Neurosciences
The Feinstein Institute for Medical Research

David Eidelberg is head of the Center for Neurosciences at The Feinstein Institute for Medical Research. He is internationally recognized for his pioneering work using functional brain imaging to identify abnormal metabolic networks in neurological disorders. This approach has provided unique insights into the circuit abnormalities that underlie a variety of brain disorders including Parkinson's disease, Huntington's disease, Tourette syndrome and torsion dystonia.

David Eidelberg is head of the Center for Neurosciences at The Feinstein Institute for Medical Research. He is

internationally recognized for his pioneering work using functional brain imaging to identify abnormal metabolic networks in neurological disorders. This approach has provided unique insights into the circuit abnormalities that underlie a variety of brain disorders including Parkinson's disease, Huntington's disease, Tourette syndrome and torsion dystonia.

Dr. Eidelberg received his MD from Harvard Medical School. After completing residency training in neurology at the Harvard-Longwood Area Training Program, he pursued postdoctoral training as a Moseley Traveling Fellow at the National Hospital, Queen Square in London UK and at Sloan-Kettering Institute in New York. Dr. Eidelberg moved to North Shore University Hospital (now North Shore-Long Island Jewish Health System) in Manhasset, New York in 1988 to establish the functional imaging laboratory and the clinical movement disorders program. In 2001 he became the founding director of the Center for Neurosciences at The Feinstein Institute for Medical Research, where he is currently Susan and Leonard Feinstein Professor of Neurology and Neuroscience.

Over the years, Dr. Eidelberg has received many research grants from NIH and private foundations. His scientific contributions have been recognized by the Fred Springer Award (2005) and the American Academy of Neurology Movement Disorders Research Award (2010). He is the author of over 350 peer-reviewed scientific articles and reviews. Dr. Eidelberg currently serves on the editorial boards of *Annals of Neurology*, *Journal of Neuroscience*, *NeuroImage*, *Journal of Nuclear Medicine*, and *Current Opinion in Neurology*. He is a member of the scientific advisory boards of the Bachmann-Strauss Dystonia & Parkinson Foundation and the Michael J. Fox Foundation.



Andrew S. Feigin, MD
Director, Laboratory of Experimental Therapeutics
Center for Neurosciences
The Feinstein Institute for Medical Research

Dr. Andrew Feigin is the Director of the Laboratory of Experimental Therapeutics for Movement Disorders at The Feinstein Institute for Medical Research and Director of the Huntington's Disease Society of America Center of Excellence at North Shore University Hospital (NSUH). Dr. Feigin has been involved in clinical research for 18 years and has been a site principal investigator on more than 30 National Institute of Health and industry sponsored clinical trials of new treatments for Huntington's disease (HD) and Parkinson's disease.

Dr. Andrew Feigin is the Director of the Laboratory of Experimental Therapeutics for Movement Disorders at The Feinstein Institute for Medical Research and Director of the Huntington's Disease Society of America Center of Excellence at North Shore University Hospital (NSUH). Dr. Feigin has been involved in clinical research for 18 years and has been a site principal investigator on more than 30 National Institute of Health and industry sponsored clinical trials of new treatments for Huntington's disease (HD) and Parkinson's disease.

His independent research focuses on using state-of-the-art imaging methods to elucidate the mechanisms underlying current therapies for movement disorders including HD. This work has resulted in numerous publications in high impact peer-reviewed medical journals. In addition, Dr. Feigin is interested in utilizing imaging as a biomarker for neurodegenerative disorders in the preclinical phase of illness.

Dr. Feigin received his MD from Columbia University in 1988. He joined NSUH in 1995 after training in Movement Disorders at the University of Rochester. He gained extensive experience with HD patient care and expertise in the experimental therapeutics of HD during his fellowship. Dr. Feigin began participation in the Venezuela Huntington's Disease Project in 1992, and continued to participate for 11 years. Within his first year at NSUH, Dr. Feigin set up an HD clinic. The clinic has subsequently become a Huntington's Disease Society of America Center of Excellence, where members of > 200 HD families have been evaluated and 175 patients are actively cared for.

Dr. Feigin has been an active member of the Huntington Study Group (HSG) since its inception, and he currently serves on the HSG Executive Committee. For the past 3 years he has chaired the Scientific Program Committee for the annual Huntington's Disease Clinical Research Symposium. In addition, Dr. Feigin was a member of the National Institutes of Neurological Disease and Stroke's Huntington's Disease Core Data Elements (CDE) committee. He also serves on the Huntington's Disease Society of America's Advocacy Task Team, and the HDSA Grants Subcommittee.